Mice with heterozygous deletion of Scn1a are a model of Dravet syndrome, an infant-onset epileptic encephalopathy most often caused by mutation of SCN1A. Scn1a+/- mice recapitulate many of the features of Dravet syndrome, including spontaneous seizures and premature lethality (Miller et al., 2014; Ogiwara et al., 2007; Yu et al., 2006). The protocol outlined below will determine in a mouse model of disease whether acute administration of OV101/Gaboxadol alters seizure threshold, activity in an open field, or anxiety-like behavior.
|Effective start/end date||9/14/17 → 9/14/20|
- Ovid Therapeutics Inc. (Prot #IS00006406)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.